Sanofi/Regeneron's Dupilumab Shines in Asthma Trial
Tuesday, November 11, 2014
Source: PharmaTimes Digital
Sanofi and Regeneron are putting their investigational monoclonal antibody, known as a dupilumab, into late-stage trials for moderate to severe asthma on the back of positive Phase IIb data.
In the study, which enrolled 776 adults with moderate-to-severe uncontrolled asthma, dupilumab showed a reduction in the annual rate of severe exacerbations compared to placebo by 64% to 75%. The drug is an interleukin 4 receptor which modulates signalling of both the IL-4 and IL-13 proteins, which are linked to inflammation.
George Yancopoulos, Regheneron chief scientific officer, said that patients with moderate-to-severe asthma “have a high unmet medical need.